Rowan University
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
2
Ending by 2030
Apr 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 6 to 18, 2026 · next Dec 6
- 1 fee due Feb 27, 2027The maintenance fee for Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of N-acetyl-aspartic acid (US 10,391,153) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 2 fees due Apr 8 to 27, 2027 · next Apr 8
- 1 fee due May 19, 2027The maintenance fee for Bandage and medical fabrics dispensers (US 10,478,357) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 2 fees due Sep 29 to 30, 2027 · next Sep 29
- 1 fee due Oct 7, 2027The maintenance fee for Processes of increasing crystallinity alignment of protein films and products thereof (US 10,611,888) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,809,631 | Targeting of podoplanin with lectin for use in the prevention and treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 8,114,593 | Cancer biomarker genes and gene products and methods for using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,664,687 | Diagnostic Autoantibody Profiles for the Detection and Diagnosis of Neurodegenerative Diseases In force · High confidence | In force | High confidence | |
| US 11,435,361 | Diagnostic Autoantibody Profiles for the Detection and Diagnosis of Neurodegenerative Diseases In force · Medium confidence | In force | Medium confidence | |
| US 9,169,327 | Targeting of podoplanin with lectin for use in the prevention and treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 10,132,817 | Diagnostic Biomarker Profiles for the Detection and Diagnosis of Alzheimer's Disease In force · High confidence | In force | High confidence | |
| US 9,746,482 | Diagnostic Biomarker Profiles for the Detection and Diagnosis of Parkinsons Disease In force · High confidence | In force | High confidence | |
| US 9,446,167 | Self-assembling biomimetic hydrogels having bioadhesive properties In force · From the USPTO record | In force | From the USPTO record | |
| US 9,649,338 | Use of silver-containing layers at implant surfaces In force · From the USPTO record | In force | From the USPTO record | |
| US 10,391,153 | Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of N-acetyl-aspartic acid In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 46: 4 patents in force now held by others · 5 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
17 pending · 12 abandoned · 34 no status recorded